2 citations,
October 2020 in “Journal of Pharmacy And Bioallied Sciences” Hydroxychloroquine and chloroquine are not recommended for COVID-19 treatment due to insufficient evidence and safety concerns.
49 citations,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
49 citations,
May 2020 in “Frontiers in Public Health” Insulin resistance linked to obesity may increase COVID-19 severity.
42 citations,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
40 citations,
October 2020 in “Diabetes and Metabolic Syndrome: Clinical Research and Reviews” Higher androgen levels might make COVID-19 worse, especially in men.
36 citations,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
27 citations,
December 2020 in “Experimental Dermatology” Grey hair and baldness may be linked to COVID-19 severity, but more analysis is needed; post-infectious hair loss is related to the severity of the disease and usually recovers within 3-6 months.
26 citations,
September 2020 in “Journal of the European Academy of Dermatology and Venereology” A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.
21 citations,
January 2021 in “Therapeutic Advances in Endocrinology and Metabolism” Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.
19 citations,
December 2021 in “Cureus” Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.
7 citations,
December 2020 in “Clinics in Dermatology” Some alopecia treatments might help treat COVID-19, but more research is needed.
6 citations,
December 2022 in “Journal of Infection” The ACE1 gene variant doesn't affect long-COVID symptoms.
6 citations,
May 2021 in “Clinical Chemistry and Laboratory Medicine” Different ACE2 gene versions may affect COVID-19 impact based on age and suggest some hair loss drugs could be potential treatments.
5 citations,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
5 citations,
May 2021 in “International Journal of Infectious Diseases” A man experienced hair loss after getting COVID-19, which improved with treatment and might have been triggered by stress related to the illness.
5 citations,
November 2020 in “medRxiv (Cold Spring Harbor Laboratory)” 5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.
4 citations,
June 2022 in “BioMed Research International” Using mesenchymal stem cells or their exosomes is safe for COVID-19 patients and helps improve lung healing and oxygen levels.
4 citations,
March 2022 in “Journal of Infection” Anti-androgen therapy might help protect against COVID-19 infection and reduce death risk.
4 citations,
May 2021 in “Journal of The European Academy of Dermatology and Venereology” Hair loss doesn't affect COVID-19 severity.
2 citations,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
1 citations,
February 2023 in “JMIR. Journal of medical internet research/Journal of medical internet research” Social media data can help track COVID-19 symptoms and predict the pandemic's status.
1 citations,
January 2022 in “Turkiye Klinikleri Journal of Dermatology” Lifestyle changes during the early COVID-19 outbreak led to more cases of acne and other skin conditions, but fewer cases of rosacea and skin infections.
1 citations,
April 2021 in “International Journal of Dermatology” Women with conditions like PCOS may have a higher risk of COVID-19, but treatments like isotretinoin could help those with acne.
1 citations,
March 2021 in “The Journal of Sexual Medicine” The letter suggests testosterone replacement therapy might worsen COVID-19 outcomes.
March 2024 in “Sudan Journal of Medical Sciences” Many doctors lack knowledge about COVID-19 skin symptoms and need better education and guidelines.
September 2023 in “Journal of the European Academy of Dermatology and Venereology” The Gabrin sign may help identify COVID-19 patients at high risk who also have hair loss due to male hormones.
May 2023 in “Dermatology Reports” The study found that skin conditions in COVID-19 patients can signal serious internal organ damage and may be life-threatening.
May 2023 in “Clinical and translational neuroscience” Tailored neurorehabilitation programs improve life quality for post-COVID-19 patients.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
April 2023 in “Research Square (Research Square)” Many healthcare workers who had Covid-19 suffer from long-term symptoms like hair loss and fatigue, especially women.